(ay-zuh-SY-tih-deen)
This page contains brief information about azacitidine and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Vidaza
FDA label information for this drug is available at DailyMed.
Use in Cancer
Azacitidine is approved to treat:
- Acute myeloid leukemia in adults who had a first complete remission after intensive induction therapy and who are not able to finish intensive curative therapy. This use is approved for the Onureg brand of azacitidine.
- Myelodysplastic syndromes (MDS).
- It is used in adults with certain types of myelodysplastic syndromes, including chronic myelomonocytic leukemia.
- It is used in children aged 1 month and older with newly diagnosed juvenile myelomonocytic leukemia.
This use is approved for the Vidaza brand of azacitidine.
Azacitidine is also being studied in the treatment of other conditions and types of cancer.
More About Azacitidine
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Azacitidine – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Clinical Trials Accepting Patients
Find Clinical Trials for Azacitidine – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
